KOSPIHolding Companies096760

JW Holdings

₩3,635▼ 0.41%2026-11-18 close
Market Cap
₩268.7B
Turnover
₩200M
Volume
60K
Shares out.
73.9M
PER
3.6×
PBR
0.9×
EPS
₩1,032
Dividend Yield
5.80%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩215 per share · Prices as of the 2026-11-18 close

01

Report overview

JW Holdings: Infusion-Led Earnings Base, Pipeline Bet on Top

JW Holdings' operating profit rose for three straight years from 2023 to 2025, yet its net profit attributable to controlling shareholders has fallen for three consecutive quarters through Q3 2026, so operating and shareholder-level earnings are moving in different directions.

  1. 1

    Operating profit in 2025 reached KRW 167.9 billion, up 14.6% from the prior year, and the operating margin rose to 17.3%.

  2. 2

    Net profit attributable to controlling shareholders in 2025 was KRW 58.5 billion, down 6.6% from the prior year.

  3. 3

    Net profit attributable to controlling shareholders in Q3 2026 was KRW 8.62 billion, down 60.1% year on year, while operating profit in the same quarter was KRW 46.7 billion, down only 1.0%.

  4. 4

    Holding-company income relies on dividends from subsidiaries and brand royalties, and press reports indicate that 81.7% of standalone assets are equity stakes in affiliates.

  5. 5

    In March 2026 the company acquired the bio-focused venture capital firm Solidarity Investment for KRW 30.6 billion, raising its subsidiary count to seven.

02

Business structure

JW Holdings is the holding company of the JW Group, holding equity stakes in subsidiaries and steering the group's overall direction. Its main income comes from dividends received from subsidiaries, brand royalties and affiliate management fees, and it also runs some businesses directly as a mixed holding structure.

The product table in its Q1 2024 quarterly report lists the holding-business share of revenue at 55.3%. Among the subsidiaries, JW Pharmaceutical is the core unit, handling prescription drugs and new drug R&D, and press reports put JW Holdings' stake in JW Pharmaceutical at 42.1%.

Its infusion-solution subsidiary anchors the group's fluid-nutrition business, and the company analysis platform Jasoseol describes its share of the domestic TPN market as above 50%.

In March 2026 the company disclosed the acquisition of the bio venture capital firm Solidarity Investment for KRW 30.6 billion, which brought the subsidiary count to seven and equals 2.45% of total assets.

With 81.7% of standalone assets tied to affiliate equity, the holding company's value depends heavily on subsidiary performance. Hanmi Science is among the pharmaceutical holding companies often compared with it, and the combination of infusion products and drug development defines the portfolio.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩244.1B₩47.2B19.3%
2025Q4₩257.6B₩38B14.7%
2026Q1₩243.2B₩51.5B21.2%
2026Q2₩266.5B₩53.8B20.2%
2026Q3₩258.2B₩46.7B18.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩864.5B₩103.3B₩22.2B11.9%20.7%247.3%
2023₩928.1B₩144.9B₩19B15.6%15.3%237.3%
2024₩887.7B₩146.5B₩62.6B16.5%27.3%139.9%
2025₩969.6B₩167.9B₩58.5B17.3%21.9%107.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Revenue rose from KRW 864.5 billion in 2022 to KRW 928.1 billion in 2023, up 7.3% year on year, fell 4.3% to KRW 887.7 billion in 2024, and climbed 9.2% to KRW 969.6 billion in 2025.

Operating profit went from KRW 103.3 billion in 2022 to KRW 144.9 billion in 2023, KRW 146.5 billion in 2024 and KRW 167.9 billion in 2025, rising for three consecutive years from 2023 through 2025. The operating margin climbed from 11.9% in 2022 to 17.3% in 2025, showing steady improvement at the operating level.

Net profit attributable to controlling shareholders moved in the opposite pattern: KRW 22.2 billion in 2022, KRW 19 billion in 2023 (down 14.1%), KRW 62.6 billion in 2024 (up 229.1%) and KRW 58.5 billion in 2025 (down 6.6%).

Because the 2024 gain in this line far exceeded the 1.1% growth in operating profit, the role of non-operating items and the allocation of profit between shareholder groups is worth checking in the detailed sections of the filings.

Net profit including non-controlling interests was KRW 115.5 billion in 2025, well above the KRW 58.5 billion attributable to controlling shareholders, so a sizable share of subsidiary earnings belongs to outside shareholders.

The debt-to-equity ratio fell from 247.3% in 2022 to 107.1% in 2025, and year-end 2025 total equity of KRW 594.6 billion included KRW 267 billion attributable to controlling shareholders. Operating cash flow increased from KRW 97.9 billion in 2024 to KRW 163.7 billion in 2025.

Quarterly revenue rose from KRW 244.1 billion in Q3 2025 to KRW 266.5 billion in Q2 2026 before reaching KRW 258.2 billion in Q3 2026, up 5.8% year on year.

Quarterly operating profit fell to KRW 38 billion in Q4 2025, recovered to KRW 53.8 billion in Q2 2026, and then dropped to KRW 46.7 billion in Q3 2026, down 1.0% year on year.

Net profit attributable to controlling shareholders peaked at KRW 22.8 billion in Q4 2025 and then declined for three straight quarters to KRW 8.62 billion in Q3 2026, and the sum over the last four quarters is KRW 71.5 billion.

The items that separate KRW 46.7 billion of operating profit from KRW 8.62 billion of attributable net profit are a point to verify in the 2026 annual report.

05

Industry analysis

JW Holdings operates in two industry settings: a domestic pharmaceutical market for infusion and nutrition products, where demand is comparatively steady, and a bio market for drug development, where results arrive over long periods.

The company analysis platform Jasoseol says the group keeps more than 50% of the domestic TPN market, which points to a strong position in the infusion segment, though this figure comes from a secondary platform and should be checked against filings or market statistics.

Drug development carries low success rates at each stage, and valuations can shift sharply with clinical results.

A company representative said the case for strategic investment in promising bio companies has grown even as the bio investment climate has weakened, which signals that the company plans to keep investing despite a difficult backdrop.

Compared with other pharmaceutical holding companies such as Hanmi Science, the group's subsidiaries span infusion, prescription drugs, diagnostics and medical devices, which gives it a broad mix.

Because the value of a holding company depends on the value of its stakes, the path from subsidiary industry conditions to holding-level results is a key link to track.

06

Outlook

The company has stated that it will expand open innovation and its financial investment portfolio. Following the March 2026 addition of Solidarity Investment, it plans to secure growth drivers through technology transfers and mergers and acquisitions.

It also intends to combine the full-cycle R&D capabilities held by JW Pharmaceutical and others, from basic research to clinical development and approval, to raise drug development efficiency.

Press reports say the company filed to be excluded from holding-company regulation under the Fair Trade Act, while stating that the structure of subsidiary stakes and the group's operating system will not change, and that brand royalties, management support, service provision and overseas operations will continue as before.

In its drug pipeline, the Q1 2024 quarterly report records that the company acquired rights in June 2020 to related substances including JW2286, which targets STAT3, and says completion of that research could contribute to STAT-related R&D, though timing and results must be checked in future filings.

Returns from the financial investment portfolio will appear as gains or losses in the investee, so the performance disclosures of Solidarity Investment's portfolio companies are the next checkpoint.

In the 2026 annual report, the gap between annual operating margin and net profit attributable to controlling shareholders is the first item to check.

07

Valuation

PER
3.6×
PBR
0.9×
ROE
26.0%
EPS
₩1,032
BPS
₩4,331
Dividend per share
₩215

Holding-company valuation is often framed by the price-to-book ratio and by the discount to the value of subsidiary stakes.

With equity attributable to controlling shareholders at KRW 267 billion at the end of 2025, the starting point is the share price relative to that book value per controlling-shareholder share base.

Press reports indicate that 81.7% of standalone assets are affiliate stakes, so the share price is directly tied to the value of those subsidiaries.

The PER depends on which earnings base is used: 2025 net profit attributable to controlling shareholders of KRW 58.5 billion and the last four quarters' total of KRW 71.5 billion reflect earnings trends differently.

How much of the sharp Q3 2026 earnings decline is captured in each base is the central interpretive question. Dividends are linked to dividend income from subsidiaries, so subsidiary earnings affect capacity for shareholder payouts.

Operating profit and operating margin have risen, but net profit attributable to controlling shareholders has moved up and down, so earnings-based multiples vary with the period chosen.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Three years of operating improvement

Operating profit rose for three consecutive years from 2023 through 2025, reaching KRW 167.9 billion in 2025. The operating margin climbed from 11.9% in 2022 to 17.3% in 2025. The debt-to-equity ratio falling from 247.3% in 2022 to 107.1% in 2025 points to a lighter financial burden.

Infusion franchise and subsidiary mix

The company analysis platform Jasoseol says the group keeps more than 50% of the domestic TPN market. Press reports put JW Holdings' stake in JW Pharmaceutical at 42.1%. Steady infusion demand and a drug pipeline sit side by side, which diversifies the subsidiary mix.

Wider investment portfolio and open innovation

In March 2026 the company acquired the bio venture capital firm Solidarity Investment for KRW 30.6 billion and consolidated it as a subsidiary. The company said it plans to expand its financial investment portfolio and strengthen open innovation.

Securing growth drivers through technology transfers and mergers and acquisitions was also presented as a direction.

09

Bear factors

Three straight quarterly declines in attributable profit

Net profit attributable to controlling shareholders in Q3 2026 was KRW 8.62 billion, down 55.7% from the prior quarter and 60.1% year on year. Operating profit in the same quarter was KRW 46.7 billion, down only 1.0%, which widened the gap between operating and shareholder-level results. Attributable net profit also fell 6.6% in 2025, so the earnings trend is not stable.

Dependence inherent in the holding structure

With 81.7% of standalone assets in affiliate equity, holding-level results depend on subsidiary dividends and royalties. Press reports say standalone total assets are below KRW 500 billion, the Fair Trade Act threshold for holding companies. When subsidiary earnings slow, holding-company income tends to move in the same direction.

Uncertain payoff from drug development

Drug development has low success rates at each stage, so clinical results can move corporate value sharply. The Q1 2024 quarterly report records that the company acquired rights to JW2286 and related substances targeting STAT3 in June 2020. Until the research is completed, its payoff is not reflected in current earnings.

10

Risk factors

Subsidiary pricing and prescription risk

If pricing cuts or generic launches hit the flagship prescription drugs of JW Pharmaceutical, the core subsidiary, prescription share and profit could fall together. Because the holding company relies on subsidiary dividends, such effects pass directly into its income. A drop in subsidiary earnings also increases volatility in profit attributable to controlling shareholders.

Drug development and portfolio investment risk

Clinical failures or the return of licensed rights could reduce the value of subsidiaries. With the bio investment climate weaker, returns from financial investments also appear with a lag.

The KRW 30.6 billion acquisition equals 2.45% of total assets, but when its results enter reported earnings must be confirmed through filings.

Governance and regulatory risk

Press reports say the company filed to be excluded from holding-company regulation under the Fair Trade Act, and that the structure of its subsidiary stakes and group operating system will not change. Intra-group and major-shareholder transactions must be checked in the notes to the periodic reports. If group structure or transaction terms change, the basis for valuing the holding company could also shift.

11

What to watch next

  1. January–February 2027 (typical timing)

    Preliminary full-year 2026 results. Check whether net profit attributable to controlling shareholders keeps declining after Q3 2026 and whether operating profit holds near the Q3 2026 level of KRW 46.7 billion.

  2. End of March 2027 (statutory filing deadline)

    Filing of the 2026 annual report. Confirm the gap between full-year net profit attributable to controlling shareholders and total net profit, the change from the 107.1% debt-to-equity ratio at end-2025, and each subsidiary's contribution.

  3. March 2027 (typical AGM timing)

    Review dividend-related and governance items on the AGM agenda. The key question is how subsidiary dividend inflows line up with the holding company's capacity to pay dividends.

  4. Mid-May 2027

    Q1 2027 quarterly report. Check whether the gap between operating profit and net profit attributable to controlling shareholders, which widened from Q4 2025 onward, begins to narrow.

12

Overall view

JW Holdings is a holding company whose operating profit and operating margin improved from 2023 through 2025. Revenue of KRW 969.6 billion and operating profit of KRW 167.9 billion in 2025 were the largest figures of the 2022–2025 period in the reported results.

Net profit attributable to controlling shareholders, however, fell to KRW 58.5 billion in 2025 and to KRW 8.62 billion in Q3 2026, the third straight quarterly decline.

Because operating and shareholder-level earnings are moving in different directions, both the composition of profit and the allocation between shareholder groups need to be examined together.

The business is a holding company that depends on subsidiary dividends and brand royalties, with JW Pharmaceutical, the infusion business and the bio venture capital firm added in March 2026 as key variables.

On the balance sheet, the debt-to-equity ratio fell to 107.1% at end-2025, but the KRW 267 billion attributable to controlling shareholders is only part of KRW 594.6 billion in total equity.

Strengths include improved profitability and the stability of the infusion business, while weaknesses include the sharp Q3 2026 profit drop and uncertainty over drug development results. The next checkpoint is the 2026 annual report. This report does not offer an investment opinion or target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. kind.krx.co.kr
  2. jasoseol.com
  3. comp.fnguide.com
  4. mt.co.kr
  5. thevc.kr
  6. investing-for-everyone.com
  7. alphasquare.co.kr
  8. bloter.net
  9. pharmstock.co.kr
  10. medipana.com
  11. judal.co.kr
  12. judal.co.kr
  13. judal.co.kr
  14. judal.co.kr
  15. judal.co.kr
  16. judal.co.kr
  17. judal.co.kr
  18. judal.co.kr

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis